An Extension Study to Evaluate the Long-Term Efficacy and Safety of BMN 190 in Patients With CLN2 Disease

NCT02485899 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

23

Enrollment

INDUSTRY

Sponsor class

Conditions

Jansky-Bielschowsky Disease
Batten Disease
Late-Infantile Neuronal Ceroid Lipofuscinosis Type 2
CLN2 Disease
CLN2 Disorder

Interventions

BIOLOGICAL: BMN 190
DEVICE: Intracerebroventricular (ICV) access device

Sponsor

BioMarin Pharmaceutical